Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro

International Journal of Antimicrobial Agents

Volumn 43, Issue 2, 2014, Pages 184-188

  Weiss, Johanna ^a   Becker, Jonas Philipp ^a   Haefeli, Walter Emil ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CYPs; Drug transporters; Interaction; PXR; Telaprevir

Indexed keywords

CYPS; DRUG TRANSPORTERS; INTERACTION; PXR; TELAPREVIR;

ANTIVIRAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; NEOPLASM PROTEINS; OLIGOPEPTIDES; P-GLYCOPROTEIN; RECEPTORS, STEROID;

EID: 84893702360     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.10.003     Document Type: Article

References (20)

1. R. Chou, D. Hartung, B. Rahman, N. Wasson, E.B. Cottrell, and R. Fu Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review Ann Intern Med 58 2013 114 123
2. T.K. Kiang, K.J. Wilby, and M.H. Ensom Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions Clin Pharmacokinet 52 2013 487 510
3. M.P. Lê, A. Gervais, C. Le Beller, K. Long, L. Larrouy, and E. Papy et al. Serious neuropsychiatric adverse effects in a hepatitis C virus/hepatitis B virus/HIV-coinfected patient receiving bosentan and telaprevir J Antimicrob Chemother 68 2013 1208 1209
4. X. Luo, J. Trevejo, R.P. van Heeswijk, F. Smith, and V. Garg Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy Antimicrob Agents Chemother 56 2012 3641 3647
5. V. Garg, R. van Heeswijk, J.E. Lee, K. Alves, P. Nadkarni, and X. Luo Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus Hepatology 54 2011 20 27
6. V. Garg, G. Chandorkar, H.F. Farmer, F. Smith, K. Alves, and R.P. van Heeswijk Effect of telaprevir on the pharmacokinetics of midazolam and digoxin J Clin Pharmacol 52 2012 1566 1573
7. Vertex Pharmaceuticals Inc. Telaprevir. Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s). 1-383. 2010. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/ 201917Orig1s000ClinPharmR.pdf [accessed 24 April 2013].
8. C. Li, T. Liu, L. Broske, J.M. Brisson, A.S. Uss, and F.G. Njoroge et al. Permeability evaluation of peptidic HCV protease inhibitors in Caco-2 cells - correlation with in vivo absorption predicted in humans Biochem Pharmacol 76 2008 1757 1764
9. A. Kunze, J. Huwyler, G. Camenisch, and H. Gutmann Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters Biochem Pharmacol 84 2012 1096 1102
10. N.C. Zembruski, G. Büchel, L. Jödicke, M. Herzog, W.E. Haefeli, and J. Weiss Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro J Antimicrob Chemother 66 2011 802 812
11. J. Weiss, M. Herzog, and W.E. Haefeli Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro Eur J Pharmacol 660 2011 298 304
12. J. Weiss, D. Theile, A. Spalwisz, J. Burhenne, K.D. Riedel, and W.E. Haefeli Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells Biochem Pharmacol 85 2013 265 273
13. J. Weiss, and W.E. Haefeli Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2 values Drug Metab Dispos 34 2006 203 207
14. B. Mégarbane, H. Alhaddad, and X. Declèves Reduced pupil diameter in volunteers on stable buprenorphine maintenance therapy with telaprevir: a drug-drug interaction involving P-glycoprotein at the blood-brain barrier? Antimicrob Agents Chemother 56 2012 6070
15. B. Ebert, A. Seidel, and A. Lampen Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists Carcinogenesis 26 2005 1754 1763
16. D.W. Nebert, T.P. Dalton, A.B. Okey, and F.J. Gonzalez Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer J Biol Chem 279 2004 23847 23850
17. X. Chu, X. Cai, D. Cui, C. Tang, A. Ghosal, and G. Chan et al. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters Drug Metab Dispos 41 2013 668 681
18. K.L. Brouwer, D. Keppler, K.A. Hoffmaster, D.A. Bow, Y. Cheng, Y. Lai International Transporter Consortium In vitro methods to support transporter evaluation in drug discovery and development Clin Pharmacol Ther 94 2013 95 112
19. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf [accessed 17 September 2013].
20. J. Weiss, D. Theile, M.A. Rüppell, T. Speck, A. Spalwisz, and W.E. Haefeli Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro Eur J Pharmacol 701 2013 168 175